Literature DB >> 10771904

Medulloblastoma--a retrospective analysis.

B S Awasthy1, C Das Gupta, R Singh, A K Patel, P K Julka.   

Abstract

A retrospective review of 45 patients was undertaken at the All India Institute of Medical Sciences to assess the outcome and prognostic factors for these patients who received post operative radiotherapy with or without chemotherapy for medulloblastoma. The median age at diagnosis was 11 years, with 34 males and 11 female patients. Thirty four tumours were confined to midline structures, and 11 were localised to one cerebellar hemisphere or involved midline and lateral structures. Complete macroscopic removal was achieved in 24 patients and subtotal removal in 21 patients. Forty one patients underwent craniospinal irradiation and 27 patients received adjuvant chemotherapy. Median overall and disease free survival was 57 and 31 months respectively and 3 year overall survival was 76%. The addition of adjuvant chemotherapy was a significant factor for disease free survival (p = 0.01) whereas extent of surgery (total vs subtotal, p = 0.01) was a significant factor for overall survival only. Eleven patients developed recurrent disease, with ten relapsing first in the posterior fossa.

Entities:  

Mesh:

Year:  1997        PMID: 10771904     DOI: 10.1007/bf02726128

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

1.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

2.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

3.  Improvements in the radiotherapy of medulloblastoma, 1946-1975.

Authors:  T G Landberg; M L Lindgren; E K Cavallin-Ståhl; G O Svahn-Tapper; G Sundbärg; S Garwicz; J A Lagergren; V L Gunnesson; A E Brun; S E Cronqvist
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

4.  Low-dose craniospinal radiation therapy for medulloblastoma.

Authors:  F E Halberg; W M Wara; L F Fippin; M S Edwards; V A Levin; R L Davis; M B Prados; C B Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-04       Impact factor: 7.038

Review 5.  Medulloblastoma in adulthood.

Authors:  L Ferrante; L Mastronardi; P Celli; M Acqui; L Cervoni; A Fortuna
Journal:  J Neurosurg Sci       Date:  1991 Jan-Mar       Impact factor: 2.279

6.  Medulloblastoma in adults: a review of 47 patients treated between 1952 and 1981.

Authors:  H J Bloom; E M Bessell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-04       Impact factor: 7.038

7.  Medulloblastoma in adults.

Authors:  P J Frost; N J Laperriere; C S Wong; M F Milosevic; W J Simpson; M Pintilie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

8.  Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management.

Authors:  G Kopelson; R M Linggood; G M Kleinman
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

9.  Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival.

Authors:  E N Hughes; J Shillito; S E Sallan; J S Loeffler; J R Cassady; N J Tarbell
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.